Press Release, 23.02.2021

GILUPI CellCollector® Technology Selected for Application in Phase I TENDU Study

GILUPI GmbH today announced that GILUPI CellCollector® is the technology of choice for the analysis of circulating tumor cells (CTCs) in a clinical trial just recently started and announced by Norwegian company Ultimovacs ASA. The trial is a phase I evaluation of a new vaccine to treat patients who suffer from prostate cancer relapse after prostatectomy.

GILUPI is the manufacturer of the GILUPI CellCollector®, the first CE labeled medical device for *in vivo* CTC collection.

During the study - called TENDU trial - the GILUPI CellCollector® will be used to assess patients CTC status at baseline screening before treatment, at the end of treatment and during follow up.

The trial is conducted at Oslo University Hospital, Norway under the supervision of principal investigator Dr. Wolfgang Lilleby.

Dr. Christian Jurinke, CEO of GILUPI GmbH comments "We are very pleased that the principal investigator, Dr. Lilleby, and the scientists at Ultimovacs selected the GILUPI CellCollector® for CTC analysis in this clinical trial. We believe that analysis of CTCs provides important insight into the patients' health status and are very proud to have the opportunity to contribute to this project which aims at providing novel and innovative treatment options for prostate cancer patients who suffer from a relapse."

Financial or other terms of the collaboration were not disclosed.

About the TENDU Trial:

The TENDU clinical trial is a first-in-human, Phase I study and the first clinical trial resulting from Ultimovacs' Tetanus-Epitope Targeting (TET)-platform. The trial is being conducted at the Oslo University Hospital, Norway, and evaluates the safety of the vaccine in prostate cancer patients who have relapsed after radical prostatectomy. The primary objective of the study is to evaluate the safety and tolerability of three different doses of the vaccine. Patients will receive the vaccine prior to obtaining standard-of-care treatment consisting of radiation and antihormone therapy and will be followed for 6 months after the last dose of the vaccine to assess immunological responses such as the activation of T cells and anti-tumor activity. Patient enrollment is expected to be completed in the first half of 2022. Further details on the study can be found on clinicaltrials.gov identifier NCT04701021.

For more information on the TENDU trial, the TET platform or Ultimovacs please visit: www.ultimovacs.com

About GILUPI

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the *in vivo* isolation of rare cells from the blood circulation. Currently, the main focus is the diagnostics market

GILUPI GmbH
Hermannswerder 20a
14473 Potsdam
Germany

Tel. +49 331 58184782
Fax +49 331 58184056

info@gilupi.com
www.gilupi.com

for cancer.The concept of personalized medicine becomes increasingly important in oncology. The identification of the right drug for the individual patient is todays challenge in clinical practice. To address this medical need, the GILUPI CellCollector® is used to enrich rare cells by immuno-capture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers in various cancer types. Isolated cells can be characterized and analyzed down to a molecular level with immunostaining, DNA- or RNA-based methods. The GILUPI CellCollector® is the first *in vivo* CTC isolation product that is CE approved.

For further information please visit: www.gilupi.com